Implementation of HPV vaccine worldwide and in Japan

Abstract

Since cervical cancer is predominant in Asia and Africa, the promotion of human papillomavirus (HPV) vaccine is a first priority in these regions. Implementation of the HPV vaccine has been reported to reduce HPV infection and decrease the incidence of condyloma, CIN2, and invasive cancer. There have been reports of herd immunity effects as the immunization coverage has increased. Worldwide, there has been a shift from a 3-dose vaccination to a 2-dose vaccination, and verification of a 1-dose vaccination has begun. Although regularly offered vaccination in Japan had begun, a suspension of the recommendation for HPV vaccination has been implemented. Low awareness of the HPV vaccine among the target population is also a problem, and further enlightenment activities are required.